The Quantellect read.As of Nov 19, 2026, 4 active firms cover Oncology Institute Inc: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $7.00 to $10.00, a moderate spread. The average target of $8.50 sits 150% above the current $3.40. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.04 next quarter toward $-0.03 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$8.50
+150.0% upside
Average target across 4 active firms as of Nov 19, 2026 vs $3.40 current
Highest Target$10.00
Average Target$8.50
Lowest Target$7.00
Detailed analyst forecasts for TOI
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate TOI a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TOI EPS & revenue forecast
EPS · NEXT QUARTER
$-0.04
Range $-0.06 – $0.00 · 5 analysts · -74% YoY
Next period, 5 analysts expect Oncology Institute Inc to earn $-0.04 a share (range $-0.06 – $0.00), versus $-0.14 a year earlier. Full-year consensus is $-0.14, growing to $-0.03 the year after.
REVENUE · NEXT QUARTER
$171.2M
Range $166.2M – $177.8M · 5 analysts · +25% YoY
Revenue is expected to reach $171.2M (range $166.2M – $177.8M), +25.3% year-over-year. Full-year consensus is $655.5M, rising to $825.5M next year.
Top analysts covering Oncology Institute Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TOI.
#1
David Larsen
BTIG
Buy
$9.00+164.7% to target
Coverage
—
+ Follow
#2
MS
Matthew Shea
Needham
Buy
$7.00+105.9% to target
Coverage
—
+ Follow
#3
BH
Ben Haynor
Lake Street
Buy
$10.00+194.1% to target
Coverage
—
+ Follow
#4
YZ
Yuan Zhi
B. Riley Securities
Buy
$8.00+135.3% to target
Coverage
—
+ Follow
TOI stock forecast FAQ
What is TOI's average 12-month price target?+
The 4 active firms with a live target average $8.50 for Oncology Institute Inc over the next 12 months, ranging from a $10.00 high to a $7.00 low, as of Nov 19, 2026.
Is TOI stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TOI?+
The Street-high target is $10.00 (Lake Street), and the Street-low is $7.00 (Needham). The average of all 4 active-firm targets is $8.50.
How many active Wall Street firms cover TOI?+
4 active firms have a recognized rating on Oncology Institute Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TOI?+
Among analysts who currently cover TOI, David Larsen of BTIG has the strongest overall Quantellect track record. Their current call is Buy with a $9.00 target.
What is Oncology Institute Inc's projected EPS for next quarter?+
The consensus estimate is $-0.04 per share (range $-0.06 – $0.00) across 5 analysts. Full-year EPS is projected at $-0.14, rising to $-0.03 the following year.
How much revenue is Oncology Institute Inc expected to report next quarter?+
Consensus revenue is $171.2M (range $166.2M – $177.8M). Full-year revenue is projected at $655.5M, growing to $825.5M next year.
Have analysts been upgrading or downgrading TOI lately?+
As of Nov 19, 2026, 4 of 4 active firms rate TOI a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TOI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.